3 ms·
From the research article: Page 2: > On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/ 42 (50%) in the placebo
by gus_massa 5y ago
From the research article:
Page 2:
> On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/ 42 (50%) in the placebo arm (OR 2·62; 95% CI: 1·09-6·31).
Page 21:
> 57 were assigned to Ivermectin group,
7 had SARS-CoV-2 RT-PCR with Ct
value >35 in the two first tests,
3 were lost for follow up,
47 were eligible for analysis
> 59 were assigned to Placebo group,
14 had SARS-CoV-2 RT-PCR with Ct
value >35 in the two first tests,
3 were lost for follow up,
42 were eligible for analysis
Note that "Ct >35" means that the viral charge was so low that after amplifying the virus 35 times they weren't able to detect it. If we add them to the people with a good outcome, we get:
41 out of 54 (76%) patients in the ivermectin arm reached the "endpoint", compared to 35 out of 56 (61%) in the placebo arm.
And this is probably not statistically significant any more.
- NonContro 5y ago"Nearly 72% of volunteers treated with ivermectin tested negative for the virus by day six. In contrast, only 50% of those who received the placebo tested negative. IN ADDITION, the study looked at culture viability, meaning how infectious the patients were, and found that only 13% of ivermectin patients were infectious after six days, compared with 50% of the placebo group – almost four times as many." It calls for a bigger study.